Janet Hsueh is a partner in the firm’s Business Law department and a member of its Technology and Life Sciences groups. Janet represents clients across the life sciences and technology industries, including private equity funds, investment banks, and public and private companies.
Her work extends to every stage of the corporate life cycle, from financing through successful initial public offering or acquisition, with a focus on public and private capital markets transactions such as IPOs, follow-on offerings and private placements of equity and debt securities. She also counsels clients on a wide array of corporate matters, including public and private securities offerings, mergers and acquisitions, securities law compliance, corporate governance, and strategic transactions.
Representative Matters
- Sionna Therapeutics in connection with its $219.2 million initial public offering
- Talaris Therapeutics in connection with its $150 million initial public offering, its “at-the-market” program and its reverse merger with Tourmaline Bio
- argenx in connection with multiple follow-on offerings of more than $1.7 billion
- Nuvalent in connection with its $190 million initial public offering
- Fusion Pharmaceuticals in connection with multiple follow-on offerings of more than $80 million, its $200 million “at-the-market” program and its acquisition by AstraZeneca for $2.4 billion
- The underwriters and/or agents in connection with multiple follow-on offerings of more than $378 million and a $212 million “at-the-market” program for Taysha Gene Therapies
- The underwriters, initial purchasers and/or agents in connection with multiple follow-on offerings of more than $363 million and a $100 million “at-the-market” program for KalVista Pharmaceuticals, Inc.
- Checkmate Pharmaceuticals in connection with its $50 million “at-the-market” program and its acquisition by Regeneron Pharmaceuticals for $250 million
- Olink in connection with its $246 million initial public offering
- The initial purchaser of Alphatec’s $405 million notes offering
- Calliditas Therapeutics in connection with its $37 million follow-on offering and its $75 million “at-the-market” program
- Allurion Technologies in connection with multiple follow-on offerings of more than $38 million
- The underwriters of Owlet, Inc.’s $34.5 million follow-on offering
- Black Diamond Therapeutics in connection with its $75 million follow-on offering
- Hansa Biopharma in connection with its $40 million global private offering
- Trillium Therapeutics in connection with multiple follow-on offerings of more than $174 million
- The underwriters of NAPCO Security Technologies’ $74 million follow-on offering
- The agent of Vertical Aerospace’s $100 million “at-the-market” program
- The initial purchaser of Zynex’s $60 million notes offering
- The agent of Hyperion DeFi’s $100 million “at-the-market” program
- Tome Biosciences in connection with its $100 million Series B financing
- Barinthus Biotherapeutics in its definitive merger agreement with Clywedog Therapeutics
- Berkshire Grey in its merger with SoftBank Group
- Magenta Therapeutics in its reverse merger with Dianthus Therapeutics
- Alvarium Investments in its business combination with Cartesian Growth Corporation, Tiedemann Advisors and TIG Advisors
- Frazier Lifesciences Acquisition Corporation in its initial public offering and business combination with NewAmsterdam Pharma
- Consonance-HFW Acquisition Corporation in its initial public offering and business combination with Surrozen
- Cerveau Technologies in its sale to Lantheus Medical Imaging
- ZOLL Medical Corporation in its acquisition of Respicardia
Areas of Practice
Credentials
Education
JD2017
Cornell Law School
BA2012
University of California, San Diego
Admissions
Bars
- New York